If we had the opportunity to gain a better understanding of the specific challenges our patients face and to minimize the uncertainty regarding how to help them, we would choose that, right? A new publication reinforces that this opportunity for clarity is already available.
In this issue, Dr. Campbell Rogers shares his perspective on the ACC statement recommendations that indicates with strong rationale that the US should adopt a coronary CTA-first strategy for diagnosing CAD and that FFRCT should be a core component of this pathway.
In 2016, the UK’s National Institute for Health and Care Excellence (NICE) released clinical guidance prioritizing a CCTA-first pathway for stable chest pain patients. This article explores the role of the guidance in better preparing UK hospitals for COVID-19.
Patients with type 2 diabetes mellitus (T2DM) are likely to experience more aggressive cardiovascular disease development and progression than are patients with other comorbidities. This article reviews the role of CCTA in diagnosing CAD in patients with T2DM.
The usual care pathway for diagnosing heart disease does not serve women well. This article reviews the gender differences in cardiovascular disease and global data that suggests how the broader use of CCTA can help bridge the gap.
When the COVID-19 pandemic hit, cardiologists convened to determine how best to care for cardiac patients during this changing environment. This article summarizes learnings from a panel of cardiologists across the US.
A review of the ADVANCE Registry one-year outcomes presented at ACC 2019, showing that the HeartFlow Analysis helped physicians more precisely stratify their patients and deliver more personalized care.